ArticlePloS one2026
Multi-year evaluation and release of improved soybean lines for resistance to Phomopsis seed decay.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soybean [Glycine max (L.) Merr.] is one of the most economically important oilseed crops grown in the world. Soybean diseases not only affect yield but can also affect seed quality resulting in significant economic losses. Phomopsis seed decay (PSD) causes poor seed quality and is one of the most damaging soybean seed diseases. Diaporthe longicolla (syn. Phomopsis longicolla) and other pathogens in the Diaporthe/Phomopsis complex are the cause of PSD. Developing and releasing PSD-resistant germplasm lines is an important step toward the development of resistant cultivars that can protect soybean from PSD seed damage. The objective of this study was to identify improved soybean lines with PSD resistance for the mid-southern U.S. after inoculation with D. longicolla in a 5-year delayed-harvest field trial. In this study, seed assays were conducted to evaluate a total of 266 soybean entries in field experiments with inoculation of D. longicolla from 2019 to 2023. Results from five years of testing showed that maturity group (MG) late III 65-414-132-1 (DS65-1) had significantly less infection (38.6%) than susceptible late III LG03-4561-14 (86.2%). Early MG IV lines 14119-211-10 and 10031-243-12 (released as DS31-243) had statistically lower levels of PSD (29.9% and 46.6%, respectively) than susceptible early IV 'LD00-3309' (63.9%). These improved breeding lines were derived from PI 587982A. Moreover, early MG V 10049-142-31 (released as DS49-142) had less infection (7.9%) than early V 'AG5335' (25.4%), and late MG IV 12060-260-2 (released as DS1260-2) had less infection (19.6%) than susceptible late IV 'P46T59R' (55.3%). DS1260-2 was derived from PI 587982A, and DS49-142 was derived from PI 603756. Resistant lines were transferred to breeders for potential use in developing soybean cultivars with resistance to PSD. This research provides useful information for the development of durable resistance to PSD, which will aid in the management of soybean seed decay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.